top of page

ESMO Congress 2021 - Mini oral session - Melanoma and other skin tumours

ESMO
9/20/21, 8:30 PM
Europe/Paris GMT+2

Description

1038MO - Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial

Presentation Number

1038MO

Speakers

  • Ivan Marquez-Rodas (Madrid, Spain)

Lecture Time

17:30 - 17:35

1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)

Presentation Number

1039MO

Speakers

  • Kim A. Margolin (Duarte, CA, United States of America)

Lecture Time

17:35 - 17:40

Discussion 1038MO and 1039MO

Speakers

  • Teresa Petrella (Toronto, Ontario, Canada)

Lecture Time

17:40 - 17:50

LBA39 - Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study

Presentation Number

LBA39

Speakers

  • Christian U. Blank (Amsterdam, Netherlands)

Lecture Time

17:50 - 17:55

LBA40 - SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study

Presentation Number

LBA40

Speakers

  • Paolo A. Ascierto (Napoli, Italy)

Lecture Time

17:55 - 18:00

1041MO - 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma

Presentation Number

1041MO

Speakers

  • Reinhard Dummer (Zurich, Switzerland)

Lecture Time

18:00 - 18:05

Discussion LBA39, LBA40 and 1041MO

Speakers

  • Teresa Troiani (Napoli, Italy)

Lecture Time

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial, CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM), Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study, SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study, 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma

Inglês

Description

Speakers

Ivan Marquez-Rodas, Kim A. Margolin, Teresa Petrella, Christian U. Blank, Paolo A. Ascierto, Reinhard Dummer, Teresa Troiani

Speakers

Link to the Event

Banner to the Event

ESMO Congress 2021 - Mini oral session - Melanoma and other skin tumours
Link to Event
Banner
Registro
bottom of page